Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice

Hepatology

Volumn 53, Issue 6, 2011, Pages 2086-2096

  Kowalik, Marta A ^a   Saliba, Christian ^a   Pibiri, Monica ^a   Perra, Andrea ^a   Ledda Columbano, Giovanna M ^a   Sarotto, Ivana ^b   Ghiso, Elena ^b   Giordano, Silvia ^b   Columbano, Amedeo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; BENZENE DERIVATIVE; DEOXYURIDINE; DIETHYLNITROSAMINE; HIPPO KINASE CASCADE; MITOGEN 1,4 BIS[2 (3,5 DICHLOROPYRDYLOXY)]BENZENE; PHOSPHOTRANSFERASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YES ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; FEMALE; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; FEMALE; HEPATOMEGALY; HYPERPLASIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED C3H; MICE, INBRED STRAINS; PHOSPHOPROTEINS; PYRIDINES;

EID: 79957465561     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24289     Document Type: Article

References (34)

1. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007; 213: 286-300.
2. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006; 43( Suppl.): S45-S53.
3. Braun L, Mead JE, Panzica M, Mikumo R, Bell GI, Fausto N. Transforming growth factor beta mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc Natl Acad Sci U S A 1988; 85: 1539-1543.
4. Columbano A, Ledda-Columbano GM, Coni PP, Faa G, Liguori C, Santa Cruz G, et al. Occurrence of cell death (apoptosis) during the involution of liver hyperplasia. Lab Invest 1985; 52: 670-675.
5. Bursch W, Lauer B, Timmermann-Trosiener I, Barthel G, Schuppler J, Schulte-Hermann R. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984; 5: 453-458.
6. Columbano A, Ledda-Columbano GM. Mitogenesis by ligands of nuclear receptors: an attractive model for the study of the molecular mechanisms implicated in liver growth. Cell Death Differ 2003; 10( Suppl. 1): S19-S21.
7. Rao MS, Reddy JK. Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis 1987; 8: 631-636.
8. Dragani TA, Manenti G, Galliani G, Della Porta G. Promoting effects of l, 4-bis[2-(3, 5-dichloropyridyloxy)]benzene in mouse hepatocarcinogenesis. Carcinogenesis 1985; 6: 225-228.
9. Peraino C, Fry RJ, Staffeldt E. Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene. Cancer Res 1971; 31: 1506-1512.
10. Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science 1990; 249: 970-971.
11. Eacho PI, Lainer TL, Brodhecker CA. Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14, 643 to clofibric acid, nafenopin and LY171883. Carcinogenesis 1991; 12: 1557-1561.
12. Lake BG, Evans JG, Morag E, Cunninghame ME, Price RJ. Comparison of the hepatic effects of nafenopin and WY-14, 643 on peroxisome proliferation and cell replication in the rat and syrian hamster. Environ Health Perspect 1993; 101: 241-247.
13. Edgar BA. From cell structure to transcription: Hippo forges a new path. Cell 2006; 124: 267-273.
14. Harvey K, Tapon N. The Salvador-Warts-Hippo pathway-an emerging tumour suppressor network. Nat Rev Cancer 2007; 7: 182-191.
15. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120-1133.
16. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007; 17: 2054-2060.
17. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-2761.
18. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009; 16: 425-438.
19. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A 2010; 107: 1437-1442.
20. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A 2010; 107: 1431-1436.
21. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125: 1253-1267.
22. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006; 103: 12405-12410.
23. Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2: 308-316.
24. Pibiri M, Ledda-Columbano GM, Cossu C, Simbula G, Menegazzi M, Shinozuka H, et al. Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3). FASEB J 2001; 15: 1006-1013.
25. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003; 278: 33334-33341.
26. Zhao B, Li L, Lei Q, Guan K. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010; 24: 862-874.
27. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, et al. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008; 39: 1582-1589.
28. Huang W, Zhang J, Washington M, Liu J, Parant JM, Lozano G, et al. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol 2005; 19: 1646-1653.
29. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 2010; 394: 623-627.
30. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115: 4576-4585.
31. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
32. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 2010; 30: 75-86.
33. Llovet J, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
34. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.